

Appendix 3F

Final share buy-back notice (except minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Neuren Pharmaceuticals Limited	72 111 496 130

We (the entity) give ASX the following information.

Description of buy-back

1	Type of buy-back	Employee share scheme
---	------------------	-----------------------

Details of all shares/units bought back

2	Number of shares/units bought back	2,500,000 unquoted ordinary shares issued under Loan Funded Share Plan (NEUAZ)
3	Total consideration paid or payable for the shares/units	In accordance with the terms of the Loan Funded Share Plan, the consideration for the shares is equal to the outstanding loan balance: 1,500,000 shares at \$1.84 per share. 1,000,000 shares at \$1.64 per share.
4	If buy-back is an on-market buy-back - highest and lowest price paid	highest price: date: lowest price: date:

+ See chapter 19 for defined terms.

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:

(Company secretary)

Date: 14 July 2020

Print name: Jon Pilcher

====